Predict your next investment

Clear Creek Bio company logo
HEALTHCARE | Biotechnology
clearcreekbio.com

See what CB Insights has to offer

Founded Year

2017

Stage

Series A | Alive

Total Raised

$7.15M

About Clear Creek Bio

Clear Creek Bio develops therapies that overcome differentiation blockade in cancer. It does so using biomarkers to ensure that each patient gets the right drug at the right dose.

Clear Creek Bio Headquarter Location

585 Massachusetts Avenue 4th Floor

Cambridge, Massachusetts, 02139,

United States

Latest Clear Creek Bio News

Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

Nov 23, 2020

X Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the treatment of Covid-19. Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19. (Credit: Daniel Roberts from Pixabay) Subscribe to our email newsletter The randomized, open label, multi-center study will enroll up to 100 non-hospitalized patients who have a positive SARS-CoV-2 test and are symptomatic to assess the antiviral activity, safety, and tolerability of brequinar. Brequinar is an orally available, potent, and selective small molecule DHODH inhibitor that has been shown in vitro to inhibit viral replication of SARS-CoV-2 as well as a broad spectrum of RNA viruses.1 Participants will receive the current standard of care and will be treated once daily for five days with either brequinar or a matching placebo. “There’s an exceptional need for oral antiviral treatments that are suitable for outpatient treatment, and we are pleased to advance brequinar into a Phase 2 clinical trial for the treatment of COVID-19,” said Vikram Sheel Kumar, M.D., Chief Executive Officer of Clear Creek Bio. “We believe brequinar’s unique drug profile, with oral bioavailability and high potency, supports its development as an oral, once-daily treatment for COVID-19.” “In addition to its demonstrated in vitro antiviral activity against SARS-CoV-2, brequinar has been previously studied in more than 1,000 patients for other medical conditions,” said John C. Pottage, Jr., M.D., Chief Medical Advisor of Clear Creek Bio. “The purpose of this clinical trial is to establish whether brequinar has the antiviral safety and tolerability profile in patients infected with SARS-CoV-2 that can support the further clinical development of brequinar for the treatment of COVID-19.” Clear Creek Bio is a private biotech company focused on developing novel therapies to address infectious disease and cancer. The company’s lead drug candidate, brequinar, is a dihydroorotate dehydrogenase (DHODH) inhibitor with high potency and short half-life. In addition to its potential as a broad spectrum antiviral, the company is evaluating brequinar as a potential treatment for acute myeloid leukemia. Related

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Clear Creek Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Clear Creek Bio is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

7,152 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,330 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Clear Creek Bio Patents

Clear Creek Bio has filed 2 patents.

The 3 most popular patent topics include:

  • Acute myeloid leukemia
  • Amines
  • Cancer treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/26/2019

Radiation protection, Pharmacokinetics, Radiation health effects, Amines, Radiobiology

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/26/2019

00/00/0000

Grant Date

00/00/0000

Title

Subscribe to see more

Related Topics

Radiation protection, Pharmacokinetics, Radiation health effects, Amines, Radiobiology

Subscribe to see more

Status

Application

Subscribe to see more

Clear Creek Bio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Clear Creek Bio Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.